News
Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug development by optimizing patient recruitment for ...
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently.
AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi .
Sanofi, Formation Bio and OpenAI have jointly designed an AI-powered tool that will be rolled out in the former's phase 3 multiple sclerosis trials.
Formation Bio and Sanofi have several long-standing collaborations focused on identifying high-potential assets and co-developing AI tools that leverage shared data and technical expertise.
French drugmaker Sanofi on Tuesday announced it is collaborating with artificial intelligence company OpenAI and Formation Bio to boost its drug development projects through the use of Artificial ...
In May 2024, French pharmaceutical giant Sanofi announced a three-way collaboration with Formation Bio and OpenAI to develop AI software for drug research.
Both Sanofi and Formation Bio plan to implement Muse in upcoming clinical trials, with Sanofi leading the initial deployment in Phase 3 studies for multiple sclerosis (MS).
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together ...
PARIS and NEW YORK and SAN FRANCISCO, Nov. 12, 2024 /PRNewswire/ -- Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results